Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;19(1):192.
doi: 10.1186/s12885-019-5394-x.

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Anne-Katrin Hickmann  1   2 , Maximilian Frick  3 , Dirk Hadaschik  3 , Florian Battke  3 , Markus Bittl  4 , Oliver Ganslandt  4 , Saskia Biskup  3   5   6 , Dennis Döcker  3   6
Affiliations

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Anne-Katrin Hickmann et al. BMC Cancer. .

Abstract

Background: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment.

Objective: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL.

Methods: Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation.

Results: NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages.

Conclusions: Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor's specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future.

Keywords: CNS-lymphoma; Cerebrospinal fluid; Circulating DNA; Liquid biopsy; Personalized medicine; Targeted therapies.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by the local ethics committee (Ethikkommission der Landesärztekammer Baden-Württemberg, F-2010-030) and undertaken in accordance with national law, institutional ethical standards, and the Helsinki Declaration. Written informed consent was provided either by the patient or a legally competent next of kin prior to the first study specific intervention.

Consent for publication

As part of the written informed consent patients were informed about possible publication of the results of this investigation. Their consent to the study included a consent to publication of data while preserving anonymity. All presented data / images are selected without compromising the patients’ anonymity. Specific consent is not applicable.

Competing interests

Saskia Biskup is a co-founder of CeGaT GmbH (Tübingen, Germany). Dirk Hadaschik, Florian Battke and Dennis Döcker are currently employed by CeGaT GmbH (Tübingen, Germany) All other authors have no conflicts of interest to declare.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Cranial imaging of # 1, 2: a, b/e, f) MRI T2 flair showing multifocal hyperintense lesions with contact to the CSF space in both patients; c, d/g, h) MRI T1 with contrast showing only sparse enhancement in both patients
Fig. 3
Fig. 3
Cranial imaging of #3–6: a) CT with contrast (#3), b) MRI T1 with contrast, c) CT with contrast (#5); In contrast to the images in Fig. 2, homogenous, strong contrast enhancement is visible. d) MRI T1 with contrast (#6) showing homogenously thickened meninges and hypervascularity over the left hemisphere
Fig. 4
Fig. 4
Venn diagram: Overlap of mutation profiles of tumor samples #1, 3, 4, 5. Note that this diagram shows the mutated genes. Therefore, the total number differs from Table 2, which shows all somatic mutations (2 independent mutations may occur within the same gene). Large copy number aberrations (CNAs) were not analyzed genome-wide, as the design of the NGS panel is optimized for the detection of single nucleotide variants (SNVs) and small copy number aberrations. All genes are listed in Table 3, their details are listed in the supplement (Additional file 1). Patients 2 and 6 were excluded from this diagram: The lymphoma sample #2 shows a divergent somatic mutation pattern (only 1 somatic mutation in MDM2) than the 4 other lymphomas and patient 6 had no somatic mutations at all, which is in accordance with the histopathologic diagnosis of absent malignancy. The mean coverage was >1000x in all tumor samples (ultra-deep sequencing)
Fig. 5
Fig. 5
cfDNA concentration in plasma vs. CSF. Fluorometric measurement of cfDNA concentration in CSF and plasma. For plasma and csf samples #1 and #2 no cfDNA could be detected, most probably due to technical reasons (explanation see text)
Fig. 6
Fig. 6
Mutant Allele Fraction in plasma and CSF of patients with feasible extraction. For plasma and csf samples #1 and #2 no cfDNA could be detected, most probably due to technical reasons (explanation see text)
See this image and copyright information in PMC

References

    1. Ferreri AJ, Marturano E. Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012;25(1):119–130. - PubMed
    1. Feiden W, Milutinovic S. Primary CNS lymphomas. Morphology and diagnosis. Pathologe. 2002;23(4):284–291. - PubMed
    1. Verploegh IS, Volovici V, Haitsma IK, Schouten JW, Dirven CM, Kros JM, Dammers R. Contemporary frameless intracranial biopsy techniques: might variation in safety and efficacy be expected? Acta Neurochir. 2015;157(11):2011–2016. - PMC - PubMed
    1. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, Levy M, Visokai V, Zavoral M, Minarik M. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013;433(2):227–234. - PubMed
    1. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579-86. 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21. - PMC - PubMed

MeSH terms

Substances